Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings Inc (IQV)
NYSE:IQV
IQV Stock Chart & Stats
$220.61
-$0.07(-0.03%)
At close: 4:00 PM EST
$220.61
-$0.07(-0.03%)
Day’s Range― - ―
52-Week Range$134.65 - $228.12
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.69M
Market Cap
$37.57B
Enterprise Value$45.96B
Total Cash (Recent Filing)$1.97B
Total Debt (Recent Filing)$15.19B
Price to Earnings (P/E)30.3
Beta0.87
Next Earnings
Feb 18, 2026EPS Estimate
3.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.00
Shares Outstanding170,300,000
10 Day Avg. Volume1,594,127
30 Day Avg. Volume1,686,847
Financial Highlights & Ratios
PEG Ratio10.65
Price to Book (P/B)5.87
Price to Sales (P/S)2.31
P/FCF Ratio16.85
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit8.56
Enterprise Value/Ebitda13.38
Forecast
1Y Price Target
$236.79Price Target Upside7.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)11.89
Revenue Forecast (FY)$16.19B
Bulls Say, Bears Say
Bulls Say
AI And Technology InvestmentIQV has invested aggressively in AI and other tools to extract increasingly valuable insights, enhancing all facets of drug development and commercialization.
Financial Performance And OutlookEasing regulatory clouds in pharma are expected to support IQVIA, as large pharma companies move on from policy-led limbo.
Market Position And DemandIQV is the largest global CRO, helping biopharma clients develop and commercialize drugs more quickly and efficiently.
Bears Say
Margin PressuresMargin headwinds in the RDS business could restrict IQV's ability to achieve meaningful adjusted EBITDA growth in 2026.
R&D Spending ChallengesIn the RDS segment, subdued R&D spending and lower B2B ratios are seen as limiting factors for top-line growth beyond 5% in 2026.
Valuation ConcernsIQV's current valuation is considered to be fairly full, indicating limited potential for further stock price appreciation.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings Inc’s price range in the past 12 months?
IQVIA Holdings Inc lowest stock price was $134.65 and its highest was $228.12 in the past 12 months.
What is IQVIA Holdings Inc’s market cap?
IQVIA Holdings Inc’s market cap is $37.57B.
When is IQVIA Holdings Inc’s upcoming earnings report date?
IQVIA Holdings Inc’s upcoming earnings report date is Feb 18, 2026 which is in 92 days.
How were IQVIA Holdings Inc’s earnings last quarter?
IQVIA Holdings Inc released its earnings results on Oct 28, 2025. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.982 by $0.018.
Is IQVIA Holdings Inc overvalued?
According to Wall Street analysts IQVIA Holdings Inc’s price is currently Undervalued.
Does IQVIA Holdings Inc pay dividends?
IQVIA Holdings Inc does not currently pay dividends.
What is IQVIA Holdings Inc’s EPS estimate?
IQVIA Holdings Inc’s EPS estimate is 3.4.
How many shares outstanding does IQVIA Holdings Inc have?
IQVIA Holdings Inc has 170,300,000 shares outstanding.
What happened to IQVIA Holdings Inc’s price movement after its last earnings report?
IQVIA Holdings Inc reported an EPS of $3 in its last earnings report, beating expectations of $2.982. Following the earnings report the stock price went up 0.322%.
Which hedge fund is a major shareholder of IQVIA Holdings Inc?
Currently, no hedge funds are holding shares in IQV
IQVIA Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$236.79 (7.33% Upside)
$236.79 (7.33% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.70%
12-Months-Change
Fundamentals
Return on Equity
19.55%
Trailing 12-Months
Asset Growth
5.69%
Trailing 12-Months
Company Description
IQVIA Holdings Inc
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a generally positive sentiment with strong financial performance, record-high free cash flow, and significant growth in net bookings and backlog. However, there were some challenges, particularly in the R&D Solutions segment and delays in mega trials. The company's focus on AI and technology advancements points to optimism for future efficiencies and growth.View all IQV earnings summariesIQV Revenue Breakdown
55.35% Research & Development Solutions
39.99% Technology & Analytics Solutions
4.66% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$236.79
▲(7.33% Upside)
Technical Analysis
Ownership Overview
0.89% Insiders
25.75% Mutual Funds
17.98% Other Institutional Investors
30.36% Public Companies and
Individual Investors